<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134939</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1536</org_study_id>
    <nct_id>NCT01134939</nct_id>
  </id_info>
  <brief_title>Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data</brief_title>
  <official_title>Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The question that prompted this study is the extent to which results from clinical trials can
      be translated into everyday practice (external validity). First and foremost are questions
      about tolerability and the efficacy of an antiretroviral combination treatment with Viramune
      and other antiretroviral partners. In particular, adverse events will be recorded depending
      on gender and the therapeutic effect will be monitored via the course of viral load and
      improvement of the immune system, based on the CD4 cell count.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Time Perspective:

      retro- and prospective
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Virologic Response (VR) After 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>VR is defined as HIV viral load of &lt; 50 copies/mL before month 36 and without subsequent rebound or change of ARV therapy. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart.
A change of ARV therapy is defined as a permanent discontinuation of Viramune®. A change in the background therapy due to toxicity or intolerance is not considered failure for the analysis. Therefore, a patient remains a treatment responder in this case if all other criteria are fulfilled. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL&lt; 50 copies/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Viral Load After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the CD4+ Cell Count After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data ( ALT) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (AST) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Gamma-GT) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">265</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV-infected women and men</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        The inclusion criteria for treatment with Viramune plus other antiretroviral combination
        drugs are to be based on the current Information for Healthcare Professionals/SPC

        Exclusion criteria:

        The inclusion criteria for treatment with Viramune plus other antiretroviral combination
        drugs are to be based on the current Information for Healthcare Professionals/SPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 23</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 10</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 11</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 14</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 19</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 26</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 28</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 33</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 8</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 9</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 31</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 29</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 27</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 17</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 34</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 22</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 6</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 12</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 16</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 32</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 15</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 25</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 21</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 20</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 24</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 7</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 13</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 18</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 30</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>December 31, 2014</results_first_submitted>
  <results_first_submitted_qc>January 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2015</results_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment-naive Female Patients</title>
          <description>Female patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="P2">
          <title>Treatment-naive Male Patients</title>
          <description>Male patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="P3">
          <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="P4">
          <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="P5">
          <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="P6">
          <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="P7">
          <title>Female Patients, Baseline Viral Load Not Documented</title>
          <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
        <group group_id="P8">
          <title>Male Patients, Baseline Viral Load Not Documented</title>
          <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Termination page not available</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): This patient set includes all HIV-1 infected patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment and of an antiretroviral combination partner.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment-naive Female Patients</title>
          <description>Female patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="B2">
          <title>Treatment-naive Male Patients</title>
          <description>Male patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="B3">
          <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="B4">
          <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="B5">
          <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="B6">
          <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="B7">
          <title>Female Patients, Baseline Viral Load Not Documented</title>
          <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
        <group group_id="B8">
          <title>Male Patients, Baseline Viral Load Not Documented</title>
          <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="19"/>
            <count group_id="B8" value="1"/>
            <count group_id="B9" value="265"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="9.7"/>
                    <measurement group_id="B2" value="39.2" spread="11.2"/>
                    <measurement group_id="B3" value="39.2" spread="9.1"/>
                    <measurement group_id="B4" value="44.2" spread="8.1"/>
                    <measurement group_id="B5" value="36.3" spread="8.0"/>
                    <measurement group_id="B6" value="43.2" spread="10.7"/>
                    <measurement group_id="B7" value="38.9" spread="8.9"/>
                    <measurement group_id="B8" value="50.0"/>
                    <measurement group_id="B9" value="39.7" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Virologic Response (VR) After 36 Months</title>
        <description>VR is defined as HIV viral load of &lt; 50 copies/mL before month 36 and without subsequent rebound or change of ARV therapy. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart.
A change of ARV therapy is defined as a permanent discontinuation of Viramune®. A change in the background therapy due to toxicity or intolerance is not considered failure for the analysis. Therefore, a patient remains a treatment responder in this case if all other criteria are fulfilled. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL&lt; 50 copies/ml.</description>
        <time_frame>36 months</time_frame>
        <population>Patients from Full Analysis Set (FAS): This patient set includes all patients in the treated set who have analysable data in at least one efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Virologic Response (VR) After 36 Months</title>
          <description>VR is defined as HIV viral load of &lt; 50 copies/mL before month 36 and without subsequent rebound or change of ARV therapy. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart.
A change of ARV therapy is defined as a permanent discontinuation of Viramune®. A change in the background therapy due to toxicity or intolerance is not considered failure for the analysis. Therefore, a patient remains a treatment responder in this case if all other criteria are fulfilled. A rebound is defined by two consecutive measurements of VL ≥ 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL&lt; 50 copies/ml.</description>
          <population>Patients from Full Analysis Set (FAS): This patient set includes all patients in the treated set who have analysable data in at least one efficacy endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Viral Load After 36 Months From Baseline</title>
        <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from FAS with values for viral load at baseline and after 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Viral Load After 36 Months From Baseline</title>
          <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
          <population>Patients from FAS with values for viral load at baseline and after 36 months.</population>
          <units>Log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="1.2"/>
                    <measurement group_id="O2" value="-2.7" spread="1.5"/>
                    <measurement group_id="O3" value="-0.3" spread="0.7"/>
                    <measurement group_id="O4" value="-0.3" spread="0.5"/>
                    <measurement group_id="O5" value="-2.4" spread="1.7"/>
                    <measurement group_id="O6" value="-1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the CD4+ Cell Count After 36 Months From Baseline</title>
        <description>The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from FAS with values for CD4+ at baseline and after 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the CD4+ Cell Count After 36 Months From Baseline</title>
          <description>The change in the Cluster of differentiation 4 (CD4+) cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
          <population>Patients from FAS with values for CD4+ at baseline and after 36 months.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.3" spread="209.9"/>
                    <measurement group_id="O2" value="216.9" spread="191.4"/>
                    <measurement group_id="O3" value="85.9" spread="196.6"/>
                    <measurement group_id="O4" value="39.8" spread="193.6"/>
                    <measurement group_id="O5" value="246.4" spread="271.2"/>
                    <measurement group_id="O6" value="137.1" spread="301.8"/>
                    <measurement group_id="O7" value="115.0"/>
                    <measurement group_id="O8" value="342.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for total cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for total cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="61.0"/>
                    <measurement group_id="O2" value="32.9" spread="20.8"/>
                    <measurement group_id="O3" value="-11.5" spread="60.3"/>
                    <measurement group_id="O4" value="43.0" spread="37.6"/>
                    <measurement group_id="O5" value="-2.0" spread="34.5"/>
                    <measurement group_id="O6" value="26.0">N=1</measurement>
                    <measurement group_id="O7" value="74.0" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for HDL cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for HDL cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="15.5"/>
                    <measurement group_id="O2" value="20.2" spread="1.0"/>
                    <measurement group_id="O3" value="9.3" spread="17.1"/>
                    <measurement group_id="O4" value="-26.5" spread="102.8"/>
                    <measurement group_id="O5" value="18.9" spread="13.1"/>
                    <measurement group_id="O7" value="5.0" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for LDL cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for LDL cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="30.3"/>
                    <measurement group_id="O2" value="27.8" spread="13.9"/>
                    <measurement group_id="O3" value="3.8" spread="24.3"/>
                    <measurement group_id="O4" value="5.0" spread="30.4"/>
                    <measurement group_id="O5" value="-9.3" spread="27.8"/>
                    <measurement group_id="O7" value="73.0" spread="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for triglycerides at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for triglycerides at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="63.1"/>
                    <measurement group_id="O2" value="-16.6" spread="32.3"/>
                    <measurement group_id="O3" value="-71.8" spread="102.2"/>
                    <measurement group_id="O4" value="-31.7" spread="90.8"/>
                    <measurement group_id="O5" value="-53.3" spread="53.7"/>
                    <measurement group_id="O6" value="160">N=1</measurement>
                    <measurement group_id="O7" value="-5.5" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for blood glucose at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for blood glucose at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="29.1"/>
                    <measurement group_id="O2" value="5.3" spread="18.6"/>
                    <measurement group_id="O3" value="0.2" spread="22.2"/>
                    <measurement group_id="O4" value="3.9" spread="7.2"/>
                    <measurement group_id="O5" value="7.2" spread="13.8"/>
                    <measurement group_id="O6" value="-27.5">N=1</measurement>
                    <measurement group_id="O7" value="-17.3" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data ( ALT) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for ALT at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data ( ALT) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for ALT at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="8.6"/>
                    <measurement group_id="O2" value="7.5" spread="13.8"/>
                    <measurement group_id="O3" value="7.7" spread="11.7"/>
                    <measurement group_id="O4" value="6.1" spread="18.7"/>
                    <measurement group_id="O5" value="0.0" spread="15.4"/>
                    <measurement group_id="O6" value="12.6" spread="34.8"/>
                    <measurement group_id="O7" value="6.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (AST) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for the AST at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (AST) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for the AST at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="9.5"/>
                    <measurement group_id="O2" value="3.0" spread="11.2"/>
                    <measurement group_id="O3" value="1.4" spread="5.6"/>
                    <measurement group_id="O4" value="0.4" spread="10.3"/>
                    <measurement group_id="O5" value="-1.7" spread="13.5"/>
                    <measurement group_id="O6" value="-0.8" spread="17.3"/>
                    <measurement group_id="O7" value="0.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Gamma-GT) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Gamma-GT) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="26.9"/>
                    <measurement group_id="O2" value="25.2" spread="15.4"/>
                    <measurement group_id="O3" value="7.0" spread="25.7"/>
                    <measurement group_id="O4" value="4.8" spread="111.7"/>
                    <measurement group_id="O5" value="20.9" spread="31.6"/>
                    <measurement group_id="O6" value="40.8" spread="61.9"/>
                    <measurement group_id="O7" value="-4.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for creatinine at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for creatinine at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.1" spread="0.2"/>
                    <measurement group_id="O4" value="-0.1" spread="0.1"/>
                    <measurement group_id="O5" value="0.0" spread="0.1"/>
                    <measurement group_id="O6" value="-0.1" spread="0.0"/>
                    <measurement group_id="O7" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for haemoglobin at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Female Patients</title>
            <description>Female patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Treatment-naive Male Patients</title>
            <description>Male patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Female Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Female patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Pretreated Male Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O5">
            <title>Pretreated Female Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Female patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O6">
            <title>Pretreated Male Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O7">
            <title>Female Patients, Baseline Viral Load Not Documented</title>
            <description>Female patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
          <group group_id="O8">
            <title>Male Patients, Baseline Viral Load Not Documented</title>
            <description>Male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data. .</description>
          <population>Patients from TS with evaluable data for haemoglobin at baseline and at month 36.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.1" spread="1.1"/>
                    <measurement group_id="O4" value="0.8" spread="1.0"/>
                    <measurement group_id="O5" value="1.1" spread="1.1"/>
                    <measurement group_id="O6" value="1.0" spread="2.4"/>
                    <measurement group_id="O7" value="0.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment-naive Patients</title>
          <description>Female and male patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="E2">
          <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Female and male patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="E3">
          <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Female and male patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="E4">
          <title>Patients With Baseline Viral Load Not Documented</title>
          <description>Female and male patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="101"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

